In 10%–16% of this hematologic malignancy, mutations in BCL11B modifying its DNA binding properties were found, whereas 10% of T‐ALL cases were characterized by elevated protein levels [10]. This evidence concerns the gene BCL11B and acute lymphoblastic leukemia.